Arcutis Biotherapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$15.9M
Doctors Paid
12,313
Transactions
87,026
2024 Total
$6.6M
Payment Breakdown by Category
Research$6.6M (41.5%)
Consulting$4.8M (30.4%)
Food & Beverage$1.9M (12.2%)
Travel$672,078 (4.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.6M | 2,052 | 41.5% |
| Consulting Fee | $4.8M | 1,936 | 30.4% |
| Food and Beverage | $1.9M | 80,326 | 12.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 684 | 11.7% |
| Travel and Lodging | $672,078 | 1,890 | 4.2% |
| Grant | $14,500 | 3 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,053 | 26 | 0.0% |
| Education | $1,443 | 109 | 0.0% |
Payments by Type
General
$9.3M
84,974 transactions
Research
$6.6M
2,052 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis | $2.5M | 5 | 980 |
| A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis | $1.7M | 3 | 431 |
| A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis | $918,457 | 7 | 302 |
| A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata | $787,706 | 0 | 188 |
| A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Scalp and Body Psoriasis (ARRECTOR) | $256,385 | 3 | 69 |
| A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies ARQ-151-301 or ARQ-151-302 | $189,623 | 1 | 55 |
| A Phase 1, Randomized, Open-label Study to Determine Safety and Pharmacokinetics of the Topical Application of ARQ-151 Cream in Healthy Japanese Volunteers | $188,198 | 0 | 3 |
| A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects with Seborrheic Dermatitis | $78,117 | 1 | 12 |
| A Phase 3, 8-Week, Parallel Group, Double blind, Vehicle-controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis (STRATUM) | $39,802 | 1 | 10 |
| A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis | $1,236 | 0 | 1 |
| A Phase 2a, Proof of Concept, 24-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects with Non-Segmental Facial Vitiligo | $102.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Howard Welgus, Md, MD | Specialist | Fenton, MO | $456,509 | $0 |
| Dr. James Del Rosso, Do, DO | MOHS-Micrographic Surgery | Las Vegas, NV | $193,255 | $0 |
| Tooraj Raoof, Md, MD | Internal Medicine | Encino, CA | $136,644 | $0 |
| Javier Alonso-Llamazares, M.d.phd, M.D.PHD | Dermatology | Coral Gables, FL | $135,217 | $0 |
| Dr. Robert Greenberg, Md, MD | Dermatology | San Ramon, CA | $132,865 | $0 |
| David Altman, Md, MD | Dermatology | Warren, MI | $128,637 | $0 |
| Dr. Pearl Kwong, Md Phd, MD PHD | Dermatology | Jacksonville, FL | $126,744 | $0 |
| Dr. Ein Song, M.d, M.D | Dermatology | Mill Creek, WA | $122,721 | $0 |
| Dr. Erik Domingues, Md, MD | Dermatology | Fall River, MA | $121,685 | $0 |
| Rebecca Smith, Md, MD | Dermatology | Fort Mill, SC | $120,388 | $0 |
| Dr. Elizabeth Kiracofe, M.d, M.D | Internal Medicine | Chicago, IL | $117,668 | $0 |
| Dr. Clive Liu, Md, MD | Dermatology | Bellevue, WA | $114,723 | $0 |
| George Drew, Do, DO | Dermatology | Marion, OH | $108,960 | $0 |
| Dr. Benjamin Lockshin, Md, MD | Dermatology | Silver Spring, MD | $107,336 | $0 |
| Leon Kircik, Md, MD | Dermatology | Lousiville, KY | $101,307 | $0 |
| Linda Stein Gold, M.d, M.D | Dermatology | West Bloomfield, MI | $98,233 | $0 |
| Omar Noor, M.d, M.D | Student in an Organized Health Care Education/Training Program | Somerset, NJ | $97,338 | $0 |
| Kristi Hawley, D.o, D.O | Dermatology | Caledonia, MI | $96,838 | $0 |
| Dr. Raj Chovatiya, M.d., Ph.d, M.D., PH.D | Dermatology | Chicago, IL | $95,193 | $0 |
| Dr. Alexandra Golant, M.d, M.D | Dermatology | New York, NY | $93,111 | $0 |
| Jennifer Soung, M.d, M.D | Dermatology | Santa Ana, CA | $90,678 | $0 |
| Dr. Joshua Zeichner, Md, MD | Dermatology | New York, NY | $86,669 | $0 |
| Michael Payette, M.d., M.b.a, M.D., M.B.A | Dermatology | Cromwell, CT | $84,858 | $0 |
| Harry Greenberg, Md, MD | Dermatology | Las Vegas, NV | $84,672 | $0 |
| Mr. Aaron Sookhoo, Pa-C, PA-C | Surgical | Brandon, FL | $81,720 | $0 |
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. has made $15.9M in payments to 12,313 healthcare providers, recorded across 87,026 transactions in the CMS Open Payments database. In 2024, the company paid $6.6M. The top product by payment volume is Zoryve ($5.9M).
Payments were distributed across 118 medical specialties. The top specialty by payment amount is Dermatology ($5.3M to 4,558 doctors).
Payment categories include: Food & Beverage ($1.9M), Consulting ($4.8M), Research ($6.6M), Travel & Lodging ($672,078).
Arcutis Biotherapeutics, Inc. is associated with 1 products in the CMS Open Payments database.